Clariane Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Clariane han disminuido a una tasa media anual de -29.9%, mientras que en la industria Healthcare los beneficios crecieron en un 12.2% anualmente. Los ingresos han ido creciendo a una tasa media de 7.9% al año.

Información clave

-36.2%

Tasa de crecimiento de los beneficios

-39.6%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare	13.4%
Tasa de crecimiento de los ingresos	7.9%
Rentabilidad financiera	-2.0%
Margen neto	-1.9%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Clariane. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

ENXTPA:CLARI Ingresos, gastos y beneficios (EUR Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Dec 23	4,996	-92	545
30 Sep 23	4,865	-32	527
30 Jun 23	4,735	28	509
31 Mar 23	4,587	32	483
31 Dec 22	4,438	36	458
30 Jun 22	4,288	85	439
31 Mar 22	4,212	92	434
31 Dec 21	4,137	100	430
30 Sep 21	4,047	76	404
30 Jun 21	3,941	60	425
31 Mar 21	3,857	50	431
31 Dec 20	3,773	39	437
30 Sep 20	3,728	57	446
30 Jun 20	3,683	74	456
31 Mar 20	3,648	94	452
31 Dec 19	3,613	115	449
30 Sep 19	3,542	117	528
30 Jun 19	3,471	119	607
31 Mar 19	3,404	121	686
31 Dec 18	3,336	123	765
30 Sep 18	3,280	152	755
30 Jun 18	3,224	180	744
31 Mar 18	3,177	172	739
31 Dec 17	3,131	163	735
30 Sep 17	3,091	150	736
30 Jun 17	3,052	137	738
31 Mar 17	3,017	134	733
31 Dec 16	2,981	131	728
30 Sep 16	2,880	87	706
30 Jun 16	2,779	42	684
31 Mar 16	2,676	50	674
31 Dec 15	2,573	59	664
30 Sep 15	2,553	77	664
30 Jun 15	2,533	95	664
31 Mar 15	2,378	78	631
31 Dec 14	2,222	61	597
30 Sep 14	1,938	44	526
30 Jun 14	1,654	27	455
31 Mar 14	1,505	28	423
31 Dec 13	1,356	29	391
30 Sep 13	1,286	29	378
30 Jun 13	1,216	29	364

Ingresos de calidad: CLARI actualmente no es rentable.

Margen de beneficios creciente: CLARI actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: CLARI no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 29.9% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de CLARI en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: CLARI no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Healthcare (4%).

Rentabilidad financiera

Alta ROE: CLARI tiene una rentabilidad financiera negativa (-0.96%), ya que actualmente no es rentable.

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Clariane Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Full year 2023 earnings released

Clariane SE to Report First Half, 2024 Results on Jul 30, 2024

Clariane SE to Report Fiscal Year 2023 Results on Feb 28, 2024

First half 2023 earnings released

Full year 2022 earnings released

Korian to Report First Half, 2023 Results on Jul 27, 2023

Recent updates

Clariane (EPA:CLARI) Takes On Some Risk With Its Use Of Debt

Price target decreased by 12% to €3.83

Clariane Confirms Rumor of Disposal of HAD/SSIAD Business in France

Price target decreased by 11% to €4.01

Full year 2023 earnings released

Elevation Healthcare Properties managed by Elevation Advisors signed an agreement to acquire Berkley Care Group Ltd from Clariane SE (ENXTPA:CLARI) for £207 million.

Investor sentiment deteriorates as stock falls 22%

Investor sentiment deteriorates as stock falls 18%

Clariane SE to Report First Half, 2024 Results on Jul 30, 2024

Is It Too Late To Consider Buying Clariane SE (EPA:CLARI)?

Price target decreased by 22% to €6.73

Investor sentiment deteriorates as stock falls 17%

These 4 Measures Indicate That Clariane (EPA:CLARI) Is Using Debt Extensively

New major risk - Share price stability

Investor sentiment deteriorates as stock falls 31%

Clariane SE to Report Fiscal Year 2023 Results on Feb 28, 2024

Now 20% undervalued after recent price drop

Calculating The Fair Value Of Clariane SE (EPA:CLARI)

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 11% to €10.44

Consensus EPS estimates fall by 82%

What Is Clariane SE's (EPA:CLARI) Share Price Doing?

First half 2023 earnings released

Clariane Announces Dividend for the Financial Year 2022, Payable on July 13, 2023

Clariane Announces Dividend for the Financial Year 2022, Payable on July 13, 2023

Upcoming dividend of €0.25 per share at 3.3% yield

Consensus EPS estimates increase by 18%

Now 21% undervalued after recent price drop

At €6.98, Is It Time To Put Korian (EPA:KORI) On Your Watch List?

These 4 Measures Indicate That Korian (EPA:KORI) Is Using Debt Extensively

Consensus EPS estimates increase by 20%

Price target decreased by 11% to €20.50

Investor sentiment deteriorates as stock falls 19%

Consensus EPS estimates fall by 50%, revenue upgraded

Price target decreased by 8.2% to €21.63

Full year 2022 earnings released

Price target decreased by 7.4% to €21.94

A Look At The Fair Value Of Korian (EPA:KORI)

Korian (ENXTPA:KORI) acquired Grupo 5 Acción y Gestión Social, S.A. from Corpfin Capital Asesores, S.A., SGEIC and others.

Should You Think About Buying Korian (EPA:KORI) Now?

Korian to Report First Half, 2023 Results on Jul 27, 2023

Does Korian (EPA:KORI) Have A Healthy Balance Sheet?

Consensus forecasts updated

Price target decreased to €24.69

Investor sentiment deteriorated over the past week

Is There Now An Opportunity In Korian (EPA:KORI)?

Is Korian (EPA:KORI) A Risky Investment?

First half 2022 earnings released

Korian Appoints Philippe Lévêque as Director and Chairman of the Ethics, Quality and CSR Committee

Upcoming dividend of €0.35 per share

Why Korian (EPA:KORI) Could Be Worth Watching

Investor sentiment deteriorated over the past week

Consensus forecasts updated

High number of new directors

Korian Proposes Dividend

Consensus forecasts updated

We Think Korian (EPA:KORI) Is Taking Some Risk With Its Debt

Full year 2021 earnings: Revenues in line with analyst expectations

Price target decreased to €32.60

Price target decreased to €34.30

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Korian (EPA:KORI) Has A Somewhat Strained Balance Sheet

Icade Santé SAS completed the acquisition of 2 nursing homes in Le Teilleul and Notre-Dame-de-Sanilhac from Korian (ENXTPA:KORI) for €13 million.

Korian (EPA:KORI) Seems To Be Using A Lot Of Debt

Korian Provides Sales Guidance for the Year 2022

Consensus forecasts updated

First half 2021 earnings released: EPS €0.31 (vs €0.13 in 1H 2020)

Desglose de ingresos y gastos
Beta